Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2014 | 1 |
2016 | 2 |
2017 | 3 |
2018 | 1 |
2023 | 1 |
2024 | 0 |
Search Results
7 results
Results by year
Filters applied: . Clear all
Page 1
EDIL3 as an Angiogenic Target of Immune Exclusion Following Checkpoint Blockade.
Cancer Immunol Res. 2023 Nov 1;11(11):1493-1507. doi: 10.1158/2326-6066.CIR-23-0171.
Cancer Immunol Res. 2023.
PMID: 37728484
Free PMC article.
Anti-CTLA-4 based therapy elicits humoral immunity to galectin-3 in patients with metastatic melanoma.
Wu X, Giobbie-Hurder A, Connolly EM, Li J, Liao X, Severgnini M, Zhou J, Rodig S, Hodi FS.
Wu X, et al.
Oncoimmunology. 2018 Mar 13;7(7):e1440930. doi: 10.1080/2162402X.2018.1440930. eCollection 2018.
Oncoimmunology. 2018.
PMID: 29900046
Free PMC article.
Item in Clipboard
Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade.
Zhou J, Mahoney KM, Giobbie-Hurder A, Zhao F, Lee S, Liao X, Rodig S, Li J, Wu X, Butterfield LH, Piesche M, Manos MP, Eastman LM, Dranoff G, Freeman GJ, Hodi FS.
Zhou J, et al.
Cancer Immunol Res. 2017 Jun;5(6):480-492. doi: 10.1158/2326-6066.CIR-16-0329. Epub 2017 May 18.
Cancer Immunol Res. 2017.
PMID: 28522460
Free PMC article.
Clinical Trial.
Item in Clipboard
Combined Anti-VEGF and Anti-CTLA-4 Therapy Elicits Humoral Immunity to Galectin-1 Which Is Associated with Favorable Clinical Outcomes.
Wu X, Li J, Connolly EM, Liao X, Ouyang J, Giobbie-Hurder A, Lawrence D, McDermott D, Murphy G, Zhou J, Piesche M, Dranoff G, Rodig S, Shipp M, Hodi FS.
Wu X, et al.
Cancer Immunol Res. 2017 Jun;5(6):446-454. doi: 10.1158/2326-6066.CIR-16-0385. Epub 2017 May 4.
Cancer Immunol Res. 2017.
PMID: 28473314
Free PMC article.
Clinical Trial.
Item in Clipboard
Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy.
Wu X, Giobbie-Hurder A, Liao X, Connelly C, Connolly EM, Li J, Manos MP, Lawrence D, McDermott D, Severgnini M, Zhou J, Gjini E, Lako A, Lipschitz M, Pak CJ, Abdelrahman S, Rodig S, Hodi FS.
Wu X, et al.
Cancer Immunol Res. 2017 Jan;5(1):17-28. doi: 10.1158/2326-6066.CIR-16-0206. Epub 2016 Dec 21.
Cancer Immunol Res. 2017.
PMID: 28003187
Free PMC article.
Item in Clipboard
VEGF Neutralization Plus CTLA-4 Blockade Alters Soluble and Cellular Factors Associated with Enhancing Lymphocyte Infiltration and Humoral Recognition in Melanoma.
Wu X, Giobbie-Hurder A, Liao X, Lawrence D, McDermott D, Zhou J, Rodig S, Hodi FS.
Wu X, et al.
Cancer Immunol Res. 2016 Oct;4(10):858-868. doi: 10.1158/2326-6066.CIR-16-0084. Epub 2016 Aug 22.
Cancer Immunol Res. 2016.
PMID: 27549123
Free PMC article.
Clinical Trial.
Item in Clipboard
Bevacizumab plus ipilimumab in patients with metastatic melanoma.
Hodi FS, Lawrence D, Lezcano C, Wu X, Zhou J, Sasada T, Zeng W, Giobbie-Hurder A, Atkins MB, Ibrahim N, Friedlander P, Flaherty KT, Murphy GF, Rodig S, Velazquez EF, Mihm MC Jr, Russell S, DiPiro PJ, Yap JT, Ramaiya N, Van den Abbeele AD, Gargano M, McDermott D.
Hodi FS, et al.
Cancer Immunol Res. 2014 Jul;2(7):632-42. doi: 10.1158/2326-6066.CIR-14-0053. Epub 2014 Apr 21.
Cancer Immunol Res. 2014.
PMID: 24838938
Free PMC article.
Clinical Trial.
Item in Clipboard
Cite
Cite